Poster Presentations: Wednesday, November 3, 2010 |

Comparison of the Effects of Aprotinin and Tranexamic Acid on Blood Loss and Related Variables After Cardiopulmonary Bypass FREE TO VIEW

Daniel R. Watson; Richard Barbosa, MD
Author and Funding Information

Riverside Methodist Hospital, Columbus, OH

Chest. 2010;138(4_MeetingAbstracts):581A. doi:10.1378/chest.10648
Text Size: A A A
Published online


PURPOSE: Aprotinin has been shown to diminish the need for blood transfusions during coronary artery bypass graft operations. However, several independent studies published in early 2006 attempted to validate the FDA’s 1993 concerns regarding renal toxicity. We examined the clinical and fiscal impact of these studies on the utilization of Aprotinin in elective coronary revascularization cases.

METHODS: We studied 1372 patients undergoing elective, first-time coronary revascularization, divided into two groups. The groups consisted of those cases (703) performed twenty-eight months prior to the publication of a major article questioning the safety of Aprotinin, and those performed during the ensuing twenty-eight months(669). These data included all patient demographics including the use of anti-thrombotic drugs before surgery, the duration of cardiopulmonary bypass and all other pertinent operative details. Transfusions, postoperative mediastinal shed blood, and adverse events were examined, as well as hospital costs.

RESULTS: All Demographic variables were similar between the treatment groups. Aprotinin utilization decreased significantly (44.6% vs 3.8%, p< 0.05) and Amicar usage significantly increased (22% vs 80.4%. p< 0.05) in the two intervals. All other clinical outcomes remained essentially equal, including the percentage of patients receiving pRBC transfusions(36% vs 38%, n.s.), mediastinal shed blood(986ml vs 1039ml, n.s.), postoperative renal dysfunction(0.7% vs 0.6%, n.s.), and all other adverse events. Cost was significantly ($2,973) decreased in the latter study group.

CONCLUSION: Safe, effective, and far less expensive alternatives to Aprotinin do not significantly increase allogeneic blood use or the volume of mediastinal shed blood.

CLINICAL IMPLICATIONS: Cost savings can be achieved in perioperative cardiac care without negatively impacting clinical outcomes.

DISCLOSURE: Daniel Watson, No Financial Disclosure Information; No Product/Research Disclosure Information

12:45 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines on the management of massive blood loss.
British Committee for Standards in Haematology | 7/18/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543